Skip to main content

Peer Review reports

From: Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

Original Submission
21 Dec 2020 Submitted Original manuscript
30 Mar 2021 Author responded Author comments - Xiaodan Yang
Resubmission - Version 2
30 Mar 2021 Submitted Manuscript version 2
28 May 2021 Reviewed Reviewer Report
4 Jun 2021 Reviewed Reviewer Report
8 Jun 2021 Reviewed Reviewer Report - Stefano Vagge
14 Jul 2021 Author responded Author comments - Xiaodan Yang
Resubmission - Version 3
14 Jul 2021 Submitted Manuscript version 3
3 Aug 2021 Reviewed Reviewer Report
6 Aug 2021 Reviewed Reviewer Report
1 Sep 2021 Author responded Author comments - Xiaodan Yang
Resubmission - Version 4
1 Sep 2021 Submitted Manuscript version 4
22 Sep 2021 Author responded Author comments - Xiaodan Yang
Resubmission - Version 5
22 Sep 2021 Submitted Manuscript version 5
30 Sep 2021 Author responded Author comments - Xiaodan Yang
Resubmission - Version 6
30 Sep 2021 Submitted Manuscript version 6
Publishing
1 Oct 2021 Editorially accepted
15 Oct 2021 Article published 10.1186/s12885-021-08824-2

You can find further information about peer review here.

Back to article page